We are live on ! Find out more
CAG

Crestwood Advisors Group Portfolio holdings

AUM $5.94B
1-Year Est. Return 18.44%
This Fund
S&P 500
This Quarter Est. Return
+9.67%
1 Year Est. Return
+18.44%
3 Year Est. Return
+65.91%
5 Year Est. Return
+80.01%
10 Year Est. Return
+299.27%
AUM
$2.52B
AUM Growth
+$249M
Cap. Flow
+$45.6M
Cap. Flow %
1.81%
Top 10 Hldgs %
28.16%
Holding
266
New
9
Increased
91
Reduced
111
Closed
9

Top Buys

Rank Stock Value
1
IJR icon
iShares Core S&P Small-Cap ETF
IJR
+$13.7M
2
STZ icon
Constellation Brands
STZ
+$6.26M
3
CSCO icon
Cisco
CSCO
+$5.83M
4
TJX icon
TJX Companies
TJX
+$5.03M
5
WMB icon
Williams Companies
WMB
+$4.48M

Top Sells

Rank Stock Value
1
EOG icon
EOG Resources
EOG
+$2.94M
2
IBB icon
iShares Biotechnology ETF
IBB
+$2.57M
3
IVV icon
iShares Core S&P 500 ETF
IVV
+$2.06M
4
PXD
Pioneer Natural Resource Co.
PXD
+$1.08M
5
BRK.B icon
Berkshire Hathaway Class B
BRK.B
+$1.04M

Sector Composition

Rank Sector Weight
1 Financials 18.37%
2 Technology 17.39%
3 Healthcare 10.53%
4 Consumer Discretionary 8.32%
5 Consumer Staples 7.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DAKT icon
251
Daktronics
DAKT
$939M
$41K ﹤0.01%
40,989
– –
NOK icon
252
Nokia
NOK
$47.5B
$37K ﹤0.01%
10,000
– –
CATX icon
253
Perspective Therapeutics
CATX
$318M
$34K ﹤0.01%
5,482
– –
FSTX
254
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$24K ﹤0.01%
3,829
– –
PTN
255
Palatin Technologies
PTN
$14.1M
$20K ﹤0.01%
20
– –
CFRX
256
DELISTED
ContraFect Corporation
CFRX
$8K ﹤0.01%
17
– –
CB icon
257
Chubb
CB
$141B
– –
-1,294
Closed -$209K
GS icon
258
Goldman Sachs
GS
$294B
– –
-1,485
Closed -$308K
HOLX
259
DELISTED
Hologic
HOLX
– –
-33,204
Closed -$68K
IEZ icon
260
iShares US Oil Equipment & Services ETF
IEZ
$350M
– –
-14,855
Closed -$262K
SDY icon
261
State Street SPDR S&P Dividend ETF
SDY
$22.2B
– –
-2,185
Closed -$224K
UPS icon
262
United Parcel Service
UPS
$89.4B
– –
-1,700
Closed -$204K
VLUE icon
263
iShares MSCI USA Value Factor ETF
VLUE
$9.16B
– –
-2,542
Closed -$209K
VTV icon
264
Vanguard Value ETF
VTV
$189B
– –
-2,449
Closed -$273K
CELG
265
DELISTED
Celgene Corp
CELG
– –
-7,252
Closed -$720K
7 8 9 10
11

Similar funds

AL
Appaloosa LP Short Hills, New Jersey $5.93B AUM 44.55% 1-Year Est. Return
CGPCS
Capital Group Private Client Services Los Angeles, California $5.93B AUM 27.73% 1-Year Est. Return
BP
BC Partners New York $5.96B AUM 15.21% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
GFM
GF Fund Management Guangzhou, China $5.98B AUM 80.99% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
CM
CastleKnight Management New York $6B AUM 121.87% 1-Year Est. Return

Crestwood Advisors Group's Q4 2019 Portfolio in Review

As of Q4 2019, Crestwood Advisors Group held 266 positions worth $2.52B, up 11% from $2.27B the previous quarter. Its ten largest holdings account for 28% of the portfolio.

Crestwood Advisors Group's Q4 2019 filing shows 9 new, 91 increased, 111 reduced and 9 closed positions. Its largest new stake was Cue Biopharma: 9,000 shares worth $4.29M. The largest sale was EOG Resources, an estimated $2.94M.

By sector, the portfolio is most concentrated in Financials at 18% of assets, up from 18% a quarter earlier, followed by Technology and Healthcare.

  • Crestwood Advisors Group's largest Q4 2019 buy was Cue Biopharma: 9,000 shares worth $4.29M.
  • Crestwood Advisors Group added most to iShares Core S&P Small-Cap ETF in Q4 2019, an estimated $13.7M increase.
  • Crestwood Advisors Group's biggest Q4 2019 reduction was EOG Resources, cutting an estimated $2.94M.
  • Crestwood Advisors Group fully exited Celgene Corp in Q4 2019, selling an estimated $720K.
  • Crestwood Advisors Group's ten largest holdings make up 28% of its $2.52B portfolio in Q4 2019.
  • Crestwood Advisors Group opened 9 new positions and closed 9 in Q4 2019.
  • Crestwood Advisors Group's portfolio value rose 11% quarter-over-quarter to $2.52B.

Based on Crestwood Advisors Group's 13F filing for Q4 2019, filed 12 Feb 2020.